abrdn Healthcare Investors (HQH): auditor change — Tekla Healthcare Investors auditor changes from Deloitte to KPMG due to independence issue

abrdn Healthcare Investors

Deloitte resigned Sept 6, 2023 due to independence issue from pending transaction – Tekla Capital Mgmt and abrdn Inc.
No disagreements or reportable events in two most recent fiscal years; prior D&T reports were unqualified.
Audit committee approved KPMG as new independent auditor for fiscal year ending Sept 30, 2023.
Neither the Fund nor anyone on its behalf consulted KPMG before engagement on accounting matters.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

abrdn Healthcare Investors engaged KPMG LLP as its auditor.

Action: engagement
Auditor: KPMG LLP

Exact text from the filing

On September 7, 2023, upon the recommendation of the Audit Committee of the Board, the Board approved the engagement of KPMG LLP (“KPMG”) as the independent registered public accounting firm for the Fund for the fiscal year ending September 30, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Deloitte & Touche LLP resigned as auditor of abrdn Healthcare Investors.

Action: resignation
Auditor: Deloitte & Touche LLP

Exact text from the filing

On September 6, 2023, Deloitte & Touche LLP (“D&T”), the independent registered public accounting firm for the Tekla Healthcare Investors (the “Fund”), resigned due to an anticipated independence issue arising as a result of a pending transaction between Tekla Capital Management LLC and abrdn Inc.

View on SEC.gov

Browse all auditor changes →

abrdn Healthcare Investors filing history →

Source: SEC EDGAR

accession 0001104659-23-100073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.